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ABSTRACT 
Objective: To develop a simple, rapid, sensitive and effective reverse phase ultra-performance liquid chromatographic method (RP-UPLC) for 
simultaneous quantification of lamivudine, abacavir and dolutegravir in pure and tablet dosage forms.  
Methods: Chromatographic separation was performed by using Waters-ACQUITY UPLC system equipped with auto sampler, photodiode array 
(PDA) detector, zodiac sil RP C18 (4.6 mm × 250 mm, 3.0 µm) column, phosphate buffer (pH 3.0) and methanol in the ratio of 30:70 %v/v have been 
delivered at a flow rate of 0.25 ml/min and the detection was carried out using a Ultraviolet (UV) detector at a wavelength of 260 nm at ambient 
column temperature. The mobile phase was used as diluent. 
Results: The retention time (Rt) for lamivudine, abacavir and dolutegravir were 1.763, 2.247 and 3.175 min respectively. A good linear response 
was obtained in the range of 15-75 µg/ml, 30-150 µg/ml and 2.5-12.5 µg/ml, respectively. The Limit of Detection (LOD) values were found to be 
0.021, 0.330 and 0.038 µg/ml, respectively and the Limit of Quantitation (LOQ) values were 0.056, 1.320 and 0.095 µg/ml, respectively.  
Conclusion: It was concluded that the developed RP-UPLC method was effective, suitable and conducive for analyzing lamivudine, abacavir and 
dolutegravir in pharmaceutical formulations. The method was quantitatively evaluated in terms of precision, linearity, accuracy (recovery), 
selectivity and robustness in accordance with standard guidelines. 
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Antiretroviral therapy (ART) has evolved significantly over the last three 
decades since the development of the first nucleoside analogues NRTIs 
(nucleoside reverse transcriptase inhibitors). Since the arrival of triple 
therapy, the challenge of sustained and complete viral suppression has 
been solved for the majority of patients [1]. The major limiting factors for 
improving the long-term success of ART are tolerability and convenient 
pill burden [2]. The latest class of the antiretroviral drugs developed was 
integrase inhibitors (INI). Dolutegravir (fig. 1) is an integrase inhibitor, 
particularly focused on maintaining a favorable safety profile and a high-
efficiency rate within a single-tablet regimen (STR). It improves 
resistance barrier and allowing co-formulation with an NRTI backbone. 
Dolutegravir has been compared against both other classes of Human 
Immunodeficiency Virus (HIV) antiretrovirals as well as other integrase 
nuclear strand inhibitors. In August 2013, Dolutegravir was approved by 
Food and Drug Administration (FDA) for its use in both patients who 
have never taken ART (ART-naïve) and patients who have taken ART 
(ART-experienced) [3-5]. It is predicted that very soon an STR containing 
dolutegravir, abacavir and lamivudine will become available. 
 
Fig. 1: Chemical structure of dolutegravir 
 
 
Abacavir (fig. 2) [6] is a synthetic analogue of the naturally occurring 
purine nucleoside, guanine and it is a type of NRTI 
(nucleoside analog reverse transcriptase inhibitor) with the HIV 
antiretroviral activity agent. It differs from other reverse 
transcriptase inhibitors (didanosine, lamivudine, stavudine, 
zalcitabine and zidovudine) in structure. It belongs to the class of a 
carbocyclic nucleosides analogue rather than a dideoxynucleoside 
analogue. It is converted by intracellular enzymes to the carbovir 
triphosphate, active metabolites. Abacavir is vigorous in vitro 
against HIV-1 and HIV-2. It is a poor inhibitor of cellular 
Deoxyribonucleic acid (DNA) polymerases α, β and γ. After oral 
administration of abacavir sulphate is rapidly absorbed and it is 
distributed extensively. An absolute bioavailability of abacavir 
sulphate is ~83%, which is not affected by food. In December 1998, 
abacavir is approved by FDA. 
 
 
Fig. 2: Chemical structure of abacavir 
 
Lamivudine (fig. 3) [7] is a drug in the same category of nucleoside 
reverse transcriptase inhibitors as abacavir. It is an analogue of 
cytidine and it can reduce both types of the reverse transcriptase 
of hepatitis B virus and HIV reverse transcriptase. Lamivudine 
administered orally, it is rapidly absorbed with a bioavailability of 
80% to 87%. FDA approval granted in 1995 for lamivudine to use 
pediatric and adult based on increases in CD4 T-lymphocyte count 
[8] on a regimen of zidovudine and lamivudine compared with 
either drug alone or compared with a combination of zalcitabine 
and zidovudine was initial approval [9]. Lamivudine is in 
combinations with several triple nucleoside analogues has been 
shown to lead to high virologic failure in previously untreated 
individuals [10-13]. 
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Fig. 3: Chemical structure of lamivudine 
 
In the literature, numerous methods were described to determine 
separately or in a combination of lamivudine, abacavir and 
dolutegravir with other drugs in pharmaceutical formulation [14-
23]. Still, very few methods were reported to determine these drugs 
simultaneously in biological matrices by using High-performance 
liquid chromatography (HPLC), titrimetry and UV-visible 
spectrophotometer [24-35]. Literature survey results, till now no 
UPLC analytical work on the determination of this combination. 
Our aim was to develop a simple, accurate, sensitive method for 
simultaneous determination of lamivudine, abacavir and dolutegravir 
in combined pharmaceutical dosage form by UPLC with UV detection, 
where simple mobile phase composition was used for 
chromatographic separation without any ion-pairing agent. Total 
retention time for analysis was short with a good resolution between 
these components. All these reasons make this new method really 
lucrative. This method was also validated for linearity, sensitivity, 
precision, accuracy, selectivity and degradation studies according to 
the International Conference on Harmonization (ICH) guidelines. 
MATERIALS AND METHODS 
Chemicals and reagents 
Lamivudine, abacavir and dolutegravir were obtained from 
Pharmatrain (Kukatpally, Hyderabad). The chemicals and solvents 
used in this study were of analytical grade and HPLC grade, 
respectively. Potassium dihydrogen phosphate (KH2PO4), di-
potassium hydrogen phosphate (K2HPO4
The chromatographic analysis was performed in an isocratic elution 
mode for 8 min run time at ambient column temperature. The 
mobile phase consists of phosphate buffer (2.95 g of potassium 
dihydrogen phosphate and 5.45 g of dipotassium hydrogen 
phosphate in 1 l Milli-Q-Water) and adjusted pH to 3.0 with 
orthophosphoric acid-methanol (30:70%v/v), the flow rate of pump 
was set to 0.25 ml/min, Zodiac SIL RP C18 column (length 250 mm × 
4.6 mm inner diameter, 3 µm particle size), the chromatogram was 
monitored with UV detector at 260 nm and injection volume was 5 
µl. The mobile phase was used as diluent. 
), orthophosphoric acid 
and acetonitrile were obtained from Merck (Mumbai, India). Milli-Q-
Water purification system manufactured by Millipore (USA) 
generated water having a resistivity of 18.2 MΩ×cm. 
Equipment 
Waters-ACQUITY UPLC consisted of binary solvent manager with part 
number: 186015001, sample manager with part number: 186015005, 
single column manager with part number: 186015007 and PDA 
detector with part number: 186015026 with Waters Empower 2 PC 
workstation used for method development and validation. 
Chromatographic conditions 
Methodology 
Preparation of standard solution 
The standard stock solution was prepared by taking accurately 
weighted 15 mg, 30 mg and 2.5 mg of lamivudine, abacavir and 
dolutegravir working standards into 10 ml clean and dried 
volumetric flask, add diluent let it be dissolved completely and using 
the same diluent make volume up to the mark. Taken 1 ml of the 
above solution into 10 ml volumetric flask and add diluent to make it 
up to the mark. For the preparation of the standard solution, 1.6 ml 
of solution was taken from above stock solution into 10 ml 
volumetric flask and added diluent to make it up to the mark. 
Preparation of sample solution  
For the preparation of sample solution, 10 tablets were accurately 
weighed and crushed to obtain a fine powder. The quantity of 
powder equivalent to 15 mg of lamivudine, 30 mg of abacavir and 
2.5 mg of dolutegravir was transferred to 10 ml volumetric flask and 
add diluent, let it be dissolved completely and using the same 
diluent make the volume up to the mark. Take 1 ml of the above 
solution into 10 ml volumetric flask and add diluent to make it up to 
the mark. The obtained solution was appropriately diluted with the 
mobile phase to get the final dilution of 0.024 mg/ml lamivudine, 
0.048 mg/ml abacavir and 0.004 mg/ml dolutegravir. 
RESULTS AND DISCUSSION 
To optimize the RP-UPLC parameters, to reach a good resolution and 
peak tailing for lamivudine, abacavir and dolutegravir, many 
chromatographic parameters were tested. Several mobile phases of 
different ratios were analyzed to get good resolution, peak shape 
and to provide sufficient selectivity for the drugs. The phosphate 
buffer provided a higher sensitivity and selectivity than other 
buffers did. Using methanol and acetonitrile as organic components 
shown results of higher sensitivity, but varying the amounts of 
methanol and acetonitrile in the mobile phase affected the 
resolution, tailing factor, theoretical plates and run time. Varying the 
pH of the mobile phase resulted in poor peak shapes and poor 
resolution. So we introduced potassium dihydrogen phosphate and 
dipotassium hydrogen phosphate into the mobile phase to adjust the 
pH of the buffer to 3.0. The optimized mobile phase consisted of 2.95 
g of potassium dihydrogen phosphate and 5.45 g of dipotassium 
hydrogen phosphate in 1 l Milli-Q-Water and adjusted pH to 3.0 with 
orthophosphoric acid-methanol (30:70 %v/v). The column elution 
was monitored at 260 nm and the injection volume was 5 µl. The 
column oven temperature was maintained at 25 °C (ambient). The 
Zodiac SIL RP C18 (4.6 mm × 250 mm with a particle size of 3 μm) 
was used with a constant flow rate of 0.25 ml/min in isocratic mode. 
Retention times (Rt) of lamivudine, abacavir and dolutegravir were 
approximately 1.763±0.06 min, 2.247±0.07 min and 3.175±0.06 min, 
respectively, in all the analytical runs. The standard and sample 
chromatograms were shown in fig. 4 and 5. 
System suitability test 
Before sample analysis, the chromatographic parameters used in 
this analysis must confirm the system suitability parameters within 
the limits. The retention time (Rt), tailing factor (T) and theoretical 
plate number (N) for the principal peak and its degradation product 
were evaluated for lamivudine, abacavir and dolutegravir. The 
tailing factors were 1.23, 1.25 and 1.29 for lamivudine, abacavir and 
dolutegravir, respectively. The theoretical plate numbers (N) were 
2755, 2190 and 2693 respectively. The retention times (Rt) of the 
drugs were 1.763 min, 2.247 min and 3.175 min respectively. 
System suitability parameters (table 1) satisfied the USP guidelines 
and ICH guidelines. 
 
Table 1: System suitability parameters 
Parameters Lamivudine Abacavir Dolutegravir 
Retention time 1.763 2.247 3.175 
USP plate count 2755 2190 2693 
USP tailing 1.23 1.25 1.29 
Standard area 935905 195063 27100 
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Fig. 4: Standard chromatogram 
 
 
Fig. 5: Sample chromatogram 
 
Table 2: Assay results from pharmaceutical formulation of lamivudine, abacavir and dolutegavir 
Drug name Label claim (mg) % assay 
Lamivudine 300 99.31 
Abacavir 600 99.22 
Dolutegravir 50 99.75 
Data of n= 2 replicates 
 
Assay of pharmaceutical formulation 
The proposed method was effectively applied to find lamivudine, 
abacavir and dolutegravir in their tablet dosage form. The results 
obtained (table 2) were comparable with the corresponding labelled 
amounts. 
Method validation 
According to the international conference on harmonization (ICH) 
guideline, ICH Q2(R1) [33], this method was validated. 
Linearity 
Calibration plots for the analytes were prepared with standard stock 
solutions to yield the concentration ranges of 15-75 µg/ml for 
lamivudine, 30-150 µg/ml for abacavir, 2.5-12.5 µg/ml for 
dolutegravir into the UPLC system. In between the ranges given 
above, five concentrations were taken and triplicate injection of each 
concentration was performed.  
Calibration curves were plotted between analyte concentrations 
versus that analyte area. Linearity regression analysis of the data 
gave correlation coefficient value, slope and intercept. For 
concentration between 15 µg/ml and 150 µg/ml, the calibration 
curves were linear. By the values of the correlation coefficients (R2
 
), 
the linearity of the calibration curves was validated. The correlation 
coefficient was 0.999 for these three drugs. The results of the 
linearity experiment were listed in table 3. Linearity graphs were 
shown in fig. 6, 7 and 8. 
Table 3: Linearity results of lamivudine, abacavir and dolutegravir 
Parameters Lamivudine Abacavir Dolutegravir 
Concentration range(µg/ml) 15-75 30-150 2.5-12.5 
Correlation coefficient 0.999 0.999 0.999 
Intercept 1397 21826 10988 
Slope 14378 6610 59803 
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Fig. 6: Linearity graph of lamivudine 
 
 
Fig. 7: Linearity graph of abacavir 
 
 
Fig. 8: Linearity graph of dolutegravir 
 
Accuracy/Recovery 
Accuracy was performed using a standard addition technique by 
recovery studies. The pre-analyzed samples were spiked with extra 
50%, 100%, and 150% of each standard lamivudine, abacavir and 
dolutegravir and by using the proposed method mixtures were 
analyzed. The recovery studies were conducted in triplicate. The 
proposed method afforded a recovery of 98.60–101.69% after the 
additional standard drug solution was spiked with the presciently 
analyzed test solutions. The recovery percentages were in the 
ranges from 98.96 to 100.92 %, from 99.80 to 101.69 % and from 
99.60 to 100.34% respectively. The values of the recovery (%) were 
shown in table 4, which indicates the accuracy of the proposed 
method.
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Table 4: Accuracy results of lamivudine, abacavir and dolutegravir 
Drug name % concentration Area Amount added (mg) Amount found (mg) % recovery mean recovery 
Lamivudine 50% 573733 7.5 7.42 98.96 99.9 
100% 1158357 15 14.98 99.9 
150% 1755375 22.5 22.70 100.92 
Abacavir 50% 732134 15 15.2 101.52 101.00 
100% 1557348 30 29.94 99.8 
150% 2380289 45 45.76 101.69 
Dolutegravir 50% 541198 1.25 1.25 100.34 99.98 
100% 1074405 2.5 2.49 99.6 
150% 1618551 3.75 3.75 100.02 
Data of n=3 replicates 
 
Precision 
For the precision, repeatability expressed the same chromate-
graphic parameters within the short time interval. For the 
intermediate precision, repeatability expressed in a different day 
under same chromatographic parameters. The same concentration 
sample was injected in six replicates for intraday (precision) and six 
replicates for interday (intermediate precision). The peak areas for 
injections recorded and then calculated % Relative Standard 
Deviation (%RSD) for intraday (precision) and interday 
(intermediate precision). The intra-day precision of the method 
ranged from 0.17 to 0.20 % RSD and inter-day precision of the 
method was found from 0.11 to 0.17 % RSD for lamivudine, abacavir 
and dolutegravir, which signify that the developed method was 
precise (table 5). The lowest values of the RSD (%) specify that the 
chosen method is repeatable. 
 
Table 5: Precision and inter-day precision results for lamivudine, abacavir and dolutegravir 
Injection Precision Inter-day precision 
Lamivudine Abacavir Dolutegravir Lamivudine Abacavir Dolutegravir 
Injection 1 641219 831356 654221 637987 828667 652517 
Injection 2 641645 831763 654574 638983 829544 654557 
Injection 3 642197 832877 655600 639198 829935 654622 
Injection 4 643020 833975 656731 639852 830731 654726 
Injection 5 644273 835545 657468 639951 830995 655234 
Injection 6 642460 833403 656718 640553 831033 655761 
Average 642469.0 833153.2 655885.3 639420.6 830151.0 654569.7 
Standard deviation 1083.8 1529.5 1302.6 899.8 942.9 1104.5 
% RSD 0.17 0.18 0.20 0.14 0.11 0.17 
Data of n= 6 replicates 
 
Limit of detection (LOD) and limit of quantification (LOQ) 
The lowest amount of analyte in the drug, which can be detected, but 
not necessarily quantified, indicates the limit of detection (LOD). The 
lowest amount of analyte in the drug, which can be quantitatively 
determined with suitable precision and accuracy indicates the limit of 
quantification (LOQ). The limit of quantification (LOQ) and limit of 
detection (LOD) were determined based on the slope and the standard 
deviation of the response using the signal-to-noise ratio (S/N) as per 
ICH guidelines Q2(R1) 2005. The LODs for lamivudine, abacavir and 
dolutegravir were found to be 0.021, 0.330 and 0.038 µg/ml and the 
LOQs were 0.056, 1.320 and 0.095 µg/ml, respectively (table 6). 
 
Table 6: LOD and LOQ values of lamivudine, abacavir and dolutegravir 
Drug LOD concentration (µg/ml) LOQ concentration (µg/ml) 
Lamivudine 0.021 0.056 
Abacavir 0.330 1.32 
Doltugravir 0.038 0.095 
 
Robustness 
Robustness of the method was performed by making slight 
deliberate changes in the analytical methodology like flow rate and 
solvent ratio. It was observed that this method did not significantly 
affect in system suitability parameters like USP tailing factor, 
theoretical plates and resolution, which confirmed that the 
developed UPLC method is robust (table 7). 
 
Table 7: Robustness study for the UPLC method 
Drug Parameter Retention time Peak area USP plate count USP tailing 
Lamivudine Flow1 1.950 712143 2504 1.26 
Flow2 1.607 731317 2563 1.25 
Low Organic 1.666 582337 2537 1.24 
High Organic 1.550 712143 2504 1.26 
Abacavir Flow1 2.475 928580 2698 1.32 
Flow2 2.039 757879 2904 1.29 
Low Organic 2.485 761420 2229 1.33 
High Organic 2.375 928580 2698 1.32 
Dolutegravir Flow1 3.488 731317 2809 1.38 
Flow2 2.877 596086 2421 1.34 
Low Organic 4.705 595173 3060 1.44 
High Organic 3.988 731317 2809 1.38 
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According to stability testing of new drug substances and products, a 
guideline of ICH desires that to clarify the inherent stability 
characteristics of the active component stress testing was 
implemented. The aim of this work was to carry out the stress 
degradation studies on the lamivudine, abacavir and dolutegravir 
using the proposed method. 
Formulation drug products were exposed to thermal stress, oxidative 
stress, photolytic, hydrolytic stress under acidic medium and basic 
medium. An ideal stability indicating method, quantifies the standard 
drug alone and also resolves its degradation products. So described 
different types of stress used were thermal, oxidative, photolytic, 
acidic and basic hydrolysis. Some unknown degradant peaks were 
observed in the acidic, basic, peroxide, photolytic and thermal studies. 
But based on the peak purity, no degradant peaks were reported at the 
retention time (Rt) of lamivudine, abacavir and dolutegravir. 
Therefore, the drugs were stable up to the specified period of 12 h 
when the proposed method is used, or they are susceptible to acids, 
alkali, hydrogen peroxide, photolytic and thermal.  
Hydrolytic degradation under acidic conditions 
Pipette 3 ml from standard stock solution containing 0.15 mg/ml, 
0.3 mg/ml and 0.025 mg/ml of lamivudine, abacavir and 
dolutegravir into a 10 ml flask and added 1.0 ml of 0.1N HCl. Then, 
the volumetric flask was kept at room temperature (RT) for 6 h and 
then neutralized with 0.1 N NaOH and filled with diluents up to the 
mark. By using 0.45-micron syringe filters, filtered the solution and 
placed in vials. The results showed multiple peaks for the 
degradation products. The degradations percentage of the drugs 
observed were 5.00%, 8.03% and 20.69% (table 8), here no 
degradant peaks were observed at a retention time (Rt) of 
lamivudine, abacavir and dolutegravir. 
Hydrolytic degradation under alkali conditions 
Pipette 3 ml from a standard stock solution containing 0.15 mg/ml, 
0.3 mg/ml and 0.025 mg/ml of lamivudine, abacavir and 
dolutegravir into a 10 ml flask and added 1 ml of 0.1N NaOH. Then, 
the volumetric flask was kept at room temperature (RT) for 6 h and 
then neutralized with 0.1N HCl and filled with diluents up to the 
mark. By using 0.45-micron syringe filters, filtered the solution and 
placed in vials. The results showed multiple peaks for the 
degradation products. The degradations percentage of the drug 
observed were 14.39%, 13.73% and 16.66% (table 8), here no 
degradant peaks were observed, at the retention time (Rt) of 
lamivudine, abacavir and dolutegravir. 
Thermal-induced degradation 
The sample treated with the thermal condition at 105 °C for 48 h. 
Then the sample was taken and diluted with diluent to prepare 45 
µg/ml, 90 µg/ml and 7.5 µg/ml of lamivudine, abacavir and 
dolutegravir respectively were injected into UPLC and it was 
analyzed. No degradant peaks were observed, at the retention time 
(Rt) of these drugs. The degradation percentages were found to be 
15.99, 4.91 and 17.11% (table 8). 
Oxidative degradation 
Pipette 3 ml from a standard stock solution containing 0.15 mg/ml, 
0.3 mg/ml and 0.025 mg/ml of lamivudine, abacavir and 
dolutegravir into a 10 ml flask and treated with 1 ml of 3% w/v of 
hydrogen peroxide as oxidation agent filled with diluents up to the 
mark. That volumetric flask was then kept at room temperature 
(RT) for 30 min. By using 0.45-micron syringe filters, filtered the 
solution and placed in vials. The observed degradation percentages 
were 9.97, 17.68 and 5.94%, respectively (table 8). No degradant 
peaks were observed at the retention time (Rt) of these drugs. 
Photolytic degradation 
The drug substances were exposed to the energy of a 1.2 million lux hr 
fluorescent light and to 200 W/Sq. the meter of UV light for approximately 
7 d. Prepared the sample solution and then analysed the sample, here no 
degradant peaks were observed at the retention time (Rt) of lamivudine, 
abacavir and doutegravir. The degradation percentages were found to be 
11.04, 16.65 and 18.24% respectively (table 8). 
 
Table 8: Degradation results of lamivudine, abacavir and dolutegravir 
Type of 
degradation 



















Acid 889116 95.00 5.00 179391 91.97 8.03 214934 79.31 20.69 
Alkali 801257 85.61 14.39 168274 86.27 13.73 225846 83.34 16.66 
Thermal 786258 84.01 15.99 185487 95.09 4.91 254892 82.89 17.11 
Oxidative 842575 90.03 9.97 160578 82.32 17.68 224635 94.06 5.94 
Photolytic 832547 88.96 11.04 162587 83.35 16.65 221578 81.76 18.24 
 
This method is specific for the determination of lamivudine, abacavir 
and dolutegravir with no interference and with good linearity, 
accuracy and precision. We achieved good separation for selected 
drugs. In addition, this separation technique uses simple, low cost 
and short runtime. The chromatographic conditions of this method 
were optimized for a short 8 min run time in RP-UPLC. It is an 
excellent method for the quantification of lamivudine, abacavir and 
dolutegravir in their pharmaceutical dosage forms. 
At present, only HPLC methods were available in this combination. 
No UPLC methods were found till date.  
CONCLUSION 
The proposed RP-UPLC method for determination of lamivudine, 
abacavir and dolutegravir was developed and validated in 
pharmaceutical formulations. The prescribed method adapted the 
use of an economical and easily available mobile phase, stationary 
phase, convenient and easy extraction procedures. The method was 
sensitive enough to detect low concentration of 0.021 µg/ml, 0.330 
µg/ml and 0.038 µg/ml for lamivudine, abacavir and dolutegravir 
respectively. Recovery of selected drugs from spiked control 
samples were>99% by using this method. A stability-indicating RP-
UPLC method for the estimation of selected drugs in their solid 
dosage forms was established and validated in accordance with the 
ICH guidelines. 
ABBREVIATION 
ART: Antiretroviral theraphy; INI: Integrase inhibitors; STR: Single tablet 
regimen; NRTIs: Nucleoside Reverse Transcriptase Inhibitors; UV 
Detector: Ultraviolet Detector; RSD: Relative standard deviation; HPLC: 
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